Lopez PD, Bhatia K, Bohra C, Mahmood K, Baruch L, Eng C (2022) Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure
the most marketed supplements include NAM, NMN, and NR
100mg vials Larger vials offer better value per milligram but require using the reconstituted solution within 30 days
VK0214, oral TR agonist for X-linked adrenoleukodystrophy (X-ALD) Recent Highlights: In June 2026, Viking announced that its working toward maintenance-dosing data for subcutaneous VK2735 and preparing to start Phase 3 trials of the oral tablet in Q4 2026, with the goal of becoming the first company to offer a dual GLP-1/GIP agonist in both oral and injectable form
Retatrutide is not yet available in the UK and has not been approved for use by any regulatory bodies it is still undergoing clinical trials to assess its safety and effectiveness
Reconstituted peptide solutions should remain refrigerated at 2C8C